NCT07214675招募中不适用
The Edison System for Treatment of Benign Prostatic Hyperplasia (BPH) Using Histotripsy
适应症
干预措施
试验速览
- 阶段
- 不适用
- 状态
- 招募中
- 入组人数
- 80
- 试验地点
- 1
- 主要终点
- Number of Index-Procedure Related Adverse Events Classified by Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE)
研究概览
简要总结
The purpose of this trial is to evaluate the safety of histotripsy using the HistoSonics Edison System for treatment of BPH.
详细描述
This is a prospective multi-center, single-arm, feasibility trial designed to evaluate the safety of the HistoSonics Histotripsy System for treatment of BPH. Following histotripsy, subjects will undergo imaging ≤ 72 hours post-index procedure. Additionally, subjects will be followed at 30-day, 90-day and 180-day timepoints.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 50 Years 至 —（Adult, Older Adult）
- 性别
- Male
- 接受健康志愿者
- 否
入选标准
- •Subject is ≥ 50 years of age.
- •Subject has signed the Ethics Committee (EC) approved trial Informed Consent Form (ICF) prior to any trial related tests/procedures and is willing to comply with trial procedures and required follow-up assessments.
- •Subject is diagnosed with BPH.
- •Subject has a Body Mass Index (BMI) <
- •Subject has an I-PSS ≥
- •Subject has a prostate volume > 30 mL and ≤ 150 mL.
- •Subject has a Qmax ≤ 15 mL/s with a voided volume of ≥ 125 mL during a uroflow test.
- •Subject accepts the potential loss of ejaculatory function.
- •Subject can tolerate general anesthesia. Index-Procedure Imaging Inclusion (Assessed day of procedure)
- •Subject has an adequate acoustic window to visualize the prostate using the HistoSonics Edison System.
- •Target treatment volume is ≥ 1 cm from the rectum as visualized on ultrasound, CT or MR imaging.
排除标准
- •Subject has a life expectancy of less than one (1) year.
- •Subject has a known sensitivity to contrast media and cannot be adequately pre-medicated.
- •Subject has a post-void residual ≥ 150 mL confirmed via ultrasound.
- •Subject has an estimated glomerular filtration rate (eGFR) ≤ 50 mL/min, ≤ 14 days prior to the planned index procedure date.
- •Subject has uncorrectable coagulopathy.
- •Subject has an International Normalized Ratio (INR) value ˃ 2.0, ≤14 days prior to the planned index procedure date.
- •Subject has had a prostatectomy.
- •Subject has acute prostatitis.
- •Subject has a diagnosis of or has received treatment for chronic prostatitis or chronic pelvic pain syndrome.
- •Subject has had a urinary tract infection (UTI) ≤ 3 months prior to the planned index procedure date.
- •Subject has bladder stones.
- •Subject is catheter dependent or has a history of intermittent self-catheterization.
- •Presence of prostatic calcifications in the planned treatment volume (PTV).
- •Presence of permanent radioactive implants in the rectal wall.
- •Subject has has a major abdominal or rectal surgery that inhibits visualization of the prostate.
- •Subject has undergone prior locoregional therapy (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
- •Subject has planned locoregional therapy 6 months post index procedure (e.g., Rezum, laser, Urolift, TURP emboli, or radiation).
- •Subjects who have active cancers (not in remission for the last two years) other than non-melanomatous skin cancers.
- •Subject is being actively treated in another pharmaceutical or device trial that has not completed its primary endpoint prior to the index procedure or may interfere with the primary outcome measure of this trial.
- •In the investigator's opinion, histotripsy is not a treatment option for the subject.
- •Subject has a concurrent condition that could jeopardize the safety of the subject or compliance with the protocol.
- •Subject's prostate is not treatable by the System's working ranges (refer to User Guide).
研究组 & 干预措施
HistoSonics Edison System
Experimental
干预措施: HistoSonics Edison System (Device)
结局指标
主要结局
Number of Index-Procedure Related Adverse Events Classified by Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE)
时间窗: 30 days post histotripsy procedure
Index procedure-related complications ≤30 days post index procedure, graded using Clavien-Dindo Classification and Common Terminology Criteria for Adverse Events (CTCAE). \[Clinical Events Committee Adjudicated\]
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
不适用
The HistoSonics Edison™ System for Treatment of Primary Solid Renal Tumors Using Histotripsy (#HOPE4KIDNEY)Renal CancerTumor, SolidKidney CancerTumor, BenignTumorNCT05820087HistoSonics, Inc.67
招募中
不适用
The HistoSonics Edison™ System for Treatment of Pancreatic Adenocarcinoma Using HistotripsyPancreas CancerAdenocarcinoma of the PancreasPancreatic CancerTumor of PancreasNCT06282809HistoSonics, Inc.50
已完成
不适用
The HistoSonics Investigational System for Treatment of Primary Solid Renal Tumors Using HistotripsyRenal CancerTumor, SolidKidney CancerTumor, BenignKidney NeoplasmsTumorNCT05432232HistoSonics, Inc.20
进行中（未招募）
不适用
Targeted Microwave Tissue Coagulation for Prostate CancerProstate CancerNCT06430749Osamu Ukimura65
已完成
不适用
Ultrasound Imaging in Finding Prostate Cancer in Patients Undergoing SurgeryProstate CancerNCT02024178NYU Langone Health34